Loading the session
Loading the session
Loading instrument
$14.78
+3.36%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
The 4 Nov 2026 close of $14.77 was 16.6% above its 50-day average ($12.67) and 11.6% above its 200-day average ($13.24). It has closed above the 200-day for 10 sessions, since 22 Oct 2026. The 50-day average crossed below the 200-day on 26 Nov 2025, 235 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
26.1M shares were sold short at the 15 Oct 2026 settlement, 3.1% of the 834.7M shares outstanding; covering them would take 8.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
1 month: +18.3% (SPY −1.6%). 3 months: +21.7% (SPY −0.4%). 1 year: +9.7% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: RDY, SPY · as of 4 Nov 2026
The 14-session relative strength index closed at 82.5 on 4 Nov 2026, its 8th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Closed at $14.77 on 4 Nov 2026: 5.7% below the 52-week high of $15.67 (26 Jun 2026) and 30.0% above the low of $11.36 (22 Jul 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
July 22, 2026
−9.39%October 29, 2025
−8.15%May 20, 2022
+7.17%